Stephan R. Targan MD is the Director of the Cedars-Sinai Inflammatory Bowel and Immunobiology Research Institute.

As a practicing gastroenterologist and professor of medicine for more than 40 years, Dr. Targan has specialized in treating the most complicated cases of inflammatory bowel disease (IBD) and has trained hundreds of medical students, interns, residents and fellows and an equal number of pre- and post-doctoral researchers and scientists.

In 1990 and even before, Dr. Targan became a vocal advocate and contributor to the body of knowledge regarding heterogeneity among the inflammatory bowel diseases, and the need to define phenotypic subgroups based on combinations of clinical, genetic and biomarker data. In this way, targets will be discovered, and treatments developed with high likelihood of efficacy in defined populations. As a basic and translational scientist, Dr. Targan has made numerous discoveries resulting in improved diagnostics and treatments for Crohn’s disease and ulcerative colitis. Notably, original findings from his laboratory led to the first biologic drugs for IBD.

In 1996, Dr. Targan co-founded Prometheus Laboratories, Inc., and also served as chief scientific officer and member of the board of directors. In 2001, Dr. Targan co-founded Santarus, Inc. and served on the board of directors. Dr. Targan is currently a founding partner and Chief Medical Officer of Precision IBD, Inc.